Charles River Laboratories Intl. Inc vs Cognizant Technology Solutions Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $301.37 (market cap $14.23B), while Cognizant Technology Solutions Corp trades at $59.28 (market cap $27.03B). The key difference: Cognizant Technology Solutions Corp is the larger of the two by market cap, and Cognizant Technology Solutions Corp pays a 2.2% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Cognizant Technology Solutions Corp for 57 Days on average.
| CRL | CTSH | |
|---|---|---|
Market Cap | $14.23B | $27.03B |
Volume | 1,176,885 | 9,883,888 |
Sector | Health | Technology |
52-Week High | $310.77 | $86.70 |
52-Week Low | $149.93 | $38.73 |
Typical Hold Time | 33 Days | 57 Days |
Enterprise Value | $17.06B | $28.08B |
Dividend Yield | — | 2.2% |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Cognizant Technology Solutions (CTSH) trades at $59.43, up 4.14% on the day, with a bullish technical signal from moving averages and support at $56. The company reported revenue of $21.11B in 2025, with a net income margin of 10.26%, and has beaten earnings estimates in two of the last three quarters. Recent news highlights its AI-driven initiatives and recognition as a top employer, reinforcing its competitive positioning in IT services.
CTSH presents a value opportunity with a P/E of 12.88 below sector averages, supported by stable cash flow and a consensus price target of $64.25. Risks include competitive pressures in IT services and potential volatility around the upcoming Q3 earnings report. The stock's current valuation and analyst buy ratings suggest upside potential, though investors should monitor execution on AI integration.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →